1. Home
  2. ULCC vs MESO Comparison

ULCC vs MESO Comparison

Compare ULCC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ULCC
  • MESO
  • Stock Information
  • Founded
  • ULCC 1994
  • MESO 2004
  • Country
  • ULCC United States
  • MESO Australia
  • Employees
  • ULCC N/A
  • MESO N/A
  • Industry
  • ULCC Air Freight/Delivery Services
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ULCC Consumer Discretionary
  • MESO Health Care
  • Exchange
  • ULCC Nasdaq
  • MESO Nasdaq
  • Market Cap
  • ULCC 1.1B
  • MESO 1.3B
  • IPO Year
  • ULCC 2021
  • MESO N/A
  • Fundamental
  • Price
  • ULCC $5.18
  • MESO $14.39
  • Analyst Decision
  • ULCC Hold
  • MESO Buy
  • Analyst Count
  • ULCC 10
  • MESO 4
  • Target Price
  • ULCC $5.17
  • MESO $18.00
  • AVG Volume (30 Days)
  • ULCC 5.1M
  • MESO 194.0K
  • Earning Date
  • ULCC 10-28-2025
  • MESO 08-28-2025
  • Dividend Yield
  • ULCC N/A
  • MESO N/A
  • EPS Growth
  • ULCC N/A
  • MESO N/A
  • EPS
  • ULCC N/A
  • MESO N/A
  • Revenue
  • ULCC $3,778,000,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • ULCC $1.48
  • MESO $293.59
  • Revenue Next Year
  • ULCC $13.13
  • MESO $218.64
  • P/E Ratio
  • ULCC N/A
  • MESO N/A
  • Revenue Growth
  • ULCC 4.60
  • MESO 191.39
  • 52 Week Low
  • ULCC $2.89
  • MESO $6.00
  • 52 Week High
  • ULCC $10.26
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • ULCC 59.72
  • MESO 48.08
  • Support Level
  • ULCC $5.09
  • MESO $12.66
  • Resistance Level
  • ULCC $6.05
  • MESO $16.27
  • Average True Range (ATR)
  • ULCC 0.37
  • MESO 0.46
  • MACD
  • ULCC 0.08
  • MESO -0.31
  • Stochastic Oscillator
  • ULCC 55.98
  • MESO 47.92

About ULCC Frontier Group Holdings Inc.

Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: